Five things for pharma marketers to know: Tuesday, May 31, 2016

1. Sen. Edward Markey (D-MA) called for a federal investigation into Purdue Pharma, OxyContin's manufacturer, after the Los Angeles Times reported that the company's painkiller wears off early in patients — which may lead to addiction. (LAT)

2. Jazz Pharmaceuticals acquired Celator Pharmaceuticals in a deal worth roughly $1.5 billion. Celator has no drugs currently on the market, but has a leukemia drug, known as Vyxeos, in its pipeline. Jazz already sells two blood cancer treatments: Erwinaze and Defitelio.

3. Intercept Pharmaceuticals won accelerated approval for Ocaliva. The drug treats patients with primary biliary cirrhosis, a condition that damages ducts that carry digestive fluid. Ocaliva is the first approved treatment for the disease in the U.S.  

4. Biogen and AbbVie received approval for their multiple-sclerosis treatment Zinbryta. The drug is administered once a month and comes with a warning for severe liver injury. (PharmaTimes)

5. Reps. Fred Upton (R-MI) and Joe Pitts (R-PA) accused the FDA of delaying off-label marketing guidelines. They wrote in a letter that the “HHS has not allowed FDA to issue its completed draft guidance addressing the scope of permissible ‘scientific exchange.'”